Arvinas LLC, of New Haven, Conn., presented preclinical data at the American Society of Clinical Oncology 2017 Genitourinary Cancers Symposiums in Orlando, Fla., showing that its oral androgen receptor (AR) Protac platform demonstrated robust and durable degradation of all clinically relevant mutant AR proteins, including 92 percent to 98 percent degradation of total AR across all cell lines, suppression of prostate-specific antigen gene expression, inhibition of cell proliferation and inducing of apoptosis of prostate cancer cell lines.